Tag Archives: gild

Gilead HCV Combo Hits In Trials, Could Broaden Market

Gilead Sciences (GILD) said Monday that its two-drug combo had succeeded against six different genotypes of the hepatitis C virus (HCV) in four late-stage clinical trials. Gilead’s studies combined sofosbuvir — which is sold separately as Sovaldi and is also an ingredient in Harvoni — with a new drug candidate called velpatasvir. Some cohorts took ribavirin, an older HCV pill, in place of velpatasvir. The patients on sofosbuvir/velpatasvir for 12

Vertex Not A Good Fit For Gilead, Says Piper Jaffray

Piper Jaffray placed its bets in the biotech M&A speculation game Friday, saying that Gilead Sciences (GILD) could acquire Incyte (INCY) or Bristol-Myers Squibb (BMY) but probably wouldn’t be as interested in Vertex Pharmaceuticals (VRTX). In a report reviewing M&A in the biopharma sector, analyst Joshua Schimmer wrote that “the best fit for Gilead is a derisked, later-stage asset or collection of assets, particularly in light of the company’s

Will The Next Hepatitis C Drugs Hit It Big?

Over the last two years, hepatitis C has produced the most epic drug launches in history. But as the fanfare dies down, investors face a key question: How much longer can this drug pipeline pop? The question is grounded in the sheer success of the existing treatments. Gilead Sciences’ (GILD) Sovaldi and Harvoni and AbbVie’s (ABBV) Viekira Pak have been curing well over 90% of the patients who take them for a few months, and in the U.S. the